JP2024507991A5 - - Google Patents
Info
- Publication number
- JP2024507991A5 JP2024507991A5 JP2023552197A JP2023552197A JP2024507991A5 JP 2024507991 A5 JP2024507991 A5 JP 2024507991A5 JP 2023552197 A JP2023552197 A JP 2023552197A JP 2023552197 A JP2023552197 A JP 2023552197A JP 2024507991 A5 JP2024507991 A5 JP 2024507991A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- dosage form
- acceptable salt
- combination
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163154281P | 2021-02-26 | 2021-02-26 | |
| US63/154,281 | 2021-02-26 | ||
| PCT/US2022/017963 WO2022183029A1 (en) | 2021-02-26 | 2022-02-25 | Methods and compositions for treating agitation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024507991A JP2024507991A (ja) | 2024-02-21 |
| JP2024507991A5 true JP2024507991A5 (cg-RX-API-DMAC7.html) | 2025-03-03 |
Family
ID=83048476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023552197A Pending JP2024507991A (ja) | 2021-02-26 | 2022-02-25 | 激越を処置するための方法及び組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20240139169A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4297871A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024507991A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117412747A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3208828A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202302094A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022183029A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL267689B2 (en) | 2016-12-31 | 2025-05-01 | Bioxcel Therapeutics Inc | Use of sublingual dexmedetomidine for the treatment of agitation |
| IL279713B2 (en) | 2018-06-27 | 2025-01-01 | Bioxcel Therapeutics Inc | Dexmedetomidine-containing layer compositions and methods for their production |
| EP3999058A4 (en) | 2019-07-19 | 2023-05-03 | Bioxcel Therapeutics, Inc. | TREATMENT SCHEMES FOR NON-SEDATING DEXMEDETOMIDIN |
| AU2020407163A1 (en) * | 2019-12-16 | 2022-07-21 | Minute Molecular Diagnostics, Inc. | Lyophilized reagents |
| EP4580619A1 (en) * | 2022-08-31 | 2025-07-09 | BioXcel Therapeutics, Inc. | Methods and compositions for treating acute stress disorder |
| US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
| WO2024211911A1 (en) * | 2023-04-07 | 2024-10-10 | Oaktree Fund Administration, Llc | Methods for treating depressive states |
| WO2024263973A1 (en) * | 2023-06-23 | 2024-12-26 | Bioxcel Therapeutics, Inc. | Dexmedetomidine treatment regimens |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1138164A1 (ru) * | 1963-04-25 | 1985-02-07 | Shadurskij Konstantin S | Антигистаминное средство "димебон |
| WO2007041697A2 (en) * | 2005-10-04 | 2007-04-12 | Medivation, Inc. | Hydrogenated pyrido-indole compounds for the treatment of huntington ' s disease |
| US20100216734A1 (en) * | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP2420235A1 (en) * | 2006-10-27 | 2012-02-22 | Medivation Neurology, Inc. | Methods and combination therapies for treating alzheimer's disease |
| CA2719824A1 (en) * | 2007-08-01 | 2009-02-05 | Medivation Neurology, Inc. | Methods and compositions for treating schizophrenia using antipsychotic combination therapy |
| NO2200610T3 (cg-RX-API-DMAC7.html) * | 2007-09-21 | 2018-06-09 | ||
| WO2009039461A2 (en) * | 2007-09-21 | 2009-03-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
| WO2010031054A1 (en) * | 2008-09-15 | 2010-03-18 | Biovista, Inc. | Compositions and methods for treating epilepsy |
| TR200903014A1 (tr) * | 2009-04-17 | 2010-11-22 | Sanovel İlaç San. Ve Ti̇c. A.Ş. | Oral yolla dağılan dimebolin bileşimleri. |
| WO2011039686A1 (en) * | 2009-09-30 | 2011-04-07 | Pfizer Inc. | Latrepirdine oral sustained release dosage forms |
| JP6013364B2 (ja) * | 2010-12-23 | 2016-10-25 | アルカーメス ファーマ アイルランド リミテッド | マルチプルapiローディングプロドラッグ |
| WO2013114400A2 (en) * | 2012-01-20 | 2013-08-08 | Rubicon Research Private Limited | Compressed pharmaceutical compositions of atypical antipsychotics |
| PL2774991T3 (pl) * | 2013-03-06 | 2018-05-30 | Life Science Inkubator Betriebs Gmbh & Co. Kg | System dostarczania leków do stosowania w leczeniu lub diagnostyce zaburzeń neurologicznych |
| CN104530413B (zh) * | 2014-10-01 | 2017-08-25 | 厦门赛诺邦格生物科技股份有限公司 | 一种多官能化h型聚乙二醇衍生物修饰的生物相关物质 |
| MA41689A (fr) * | 2014-10-15 | 2017-08-22 | Bioxcel Corp | Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine |
| WO2016061554A1 (en) * | 2014-10-16 | 2016-04-21 | Bioxcel Corporation | Synergistic composition of known, safe pharmaceuticals for use in insomnia and a method of treatment thereof |
| IL267689B2 (en) * | 2016-12-31 | 2025-05-01 | Bioxcel Therapeutics Inc | Use of sublingual dexmedetomidine for the treatment of agitation |
| IL279713B2 (en) * | 2018-06-27 | 2025-01-01 | Bioxcel Therapeutics Inc | Dexmedetomidine-containing layer compositions and methods for their production |
| EP3999058A4 (en) * | 2019-07-19 | 2023-05-03 | Bioxcel Therapeutics, Inc. | TREATMENT SCHEMES FOR NON-SEDATING DEXMEDETOMIDIN |
| JP2023545372A (ja) * | 2020-10-08 | 2023-10-30 | バイオエクセル セラピューティクス,インコーポレイテッド | デクスメデトミジン塩酸塩を用いた双極性障害及び精神病の治療 |
-
2022
- 2022-02-25 EP EP22760513.6A patent/EP4297871A4/en active Pending
- 2022-02-25 CN CN202280027623.0A patent/CN117412747A/zh active Pending
- 2022-02-25 US US18/278,786 patent/US20240139169A1/en not_active Abandoned
- 2022-02-25 JP JP2023552197A patent/JP2024507991A/ja active Pending
- 2022-02-25 CA CA3208828A patent/CA3208828A1/en active Pending
- 2022-02-25 WO PCT/US2022/017963 patent/WO2022183029A1/en not_active Ceased
- 2022-02-25 TW TW111107146A patent/TW202302094A/zh unknown
-
2024
- 2024-08-22 US US18/812,515 patent/US20250228833A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9782403B2 (en) | Treating sexual desire disorders with flibanserin | |
| JP6491174B2 (ja) | ニタゾキサニドの制御放出医薬配合物 | |
| JP5553452B2 (ja) | ブリバラセタムを含む医薬組成物 | |
| EP3417861B1 (en) | Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof | |
| CN101384545B (zh) | 氘化的儿茶酚胺衍生物及包含所述化合物的药物 | |
| AU2011290614B2 (en) | Nalbuphine-based formulations and uses thereof | |
| JP2023551427A (ja) | 口腔粘膜送達のための急速注入組成物及び方法 | |
| EP2921170A1 (en) | Combination immediate release controlled release levodopa/carbidopa dosage forms | |
| TW200900094A (en) | Solid preparation | |
| JP7137850B2 (ja) | バレニクリンまたはその薬学的に許容可能な塩の包接複合体を含む口腔投与用製剤 | |
| JPH08505379A (ja) | パーキンソン病およびパーキンソン病症候群の治療のためのカルバマゼピンおよびオキカルバゼピンの用途 | |
| MXPA06012116A (es) | Uso de flibanserina en el tratamiento del trastornos premestruales y otros trastornos sexuales femeninos. | |
| JP2007508336A5 (cg-RX-API-DMAC7.html) | ||
| US11779559B2 (en) | Compositions for treating fungal and bacterial biofilms and methods of using the same | |
| JP2020523335A5 (cg-RX-API-DMAC7.html) | ||
| EP2496217B1 (en) | Direct compression tablets of otilonium | |
| CN117412747A (zh) | 用于治疗激越的方法和组合物 | |
| JP2022504181A5 (cg-RX-API-DMAC7.html) | ||
| CN111065384A (zh) | 扑热息痛的口腔崩解膜组合物 | |
| CN116036079B (zh) | 一种复合物的药物组合物及其制备方法 | |
| ZA200409237B (en) | Immediate release pharmaceutical formulation. | |
| WO2021261837A1 (ko) | 나파모스타트 메실레이트를 유효성분으로 포함하는 경구용 약제학적 조성물 | |
| ES2617657T3 (es) | Derivado de metastina y uso del mismo | |
| WO2018062685A1 (ko) | 칸데사르탄 및 암로디핀을 포함하는 단일층으로 이루어진 복합제 | |
| CN1112929C (zh) | 含有咪唑拉汀的缓释药物制剂 |